TOBRAMYCIN SULFATE (PHARMACY BULK) Drug Patent Profile

When do Tobramycin Sulfate (pharmacy Bulk) patents expire, and what generic alternatives are available?

Tobramycin Sulfate (pharmacy Bulk) is a drug marketed by Fresenius Kabi Usa, Gland, and Hospira. and is included in three NDAs.

The generic ingredient in TOBRAMYCIN SULFATE (PHARMACY BULK) is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tobramycin Sulfate (pharmacy Bulk)

A generic version of TOBRAMYCIN SULFATE (PHARMACY BULK) was approved as tobramycin sulfate by HIKMA on April 26^th, 1991.

Summary for TOBRAMYCIN SULFATE (PHARMACY BULK)

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Clinical Trials:	5
DailyMed Link:	TOBRAMYCIN SULFATE (PHARMACY BULK) at DailyMed

Recent Clinical Trials for TOBRAMYCIN SULFATE (PHARMACY BULK)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Madonna Magdy Fahmy	Early Phase 1
Joint Purification Systems	Phase 2
Osteal Therapeutics, Inc.	Phase 2

See all TOBRAMYCIN SULFATE (PHARMACY BULK) clinical trials

Pharmacology for TOBRAMYCIN SULFATE (PHARMACY BULK)

Drug Class

Aminoglycoside Antibacterial

US Patents and Regulatory Information for TOBRAMYCIN SULFATE (PHARMACY BULK)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	TOBRAMYCIN SULFATE (PHARMACY BULK)	tobramycin sulfate	INJECTABLE;INJECTION	065120-001	Nov 29, 2002	AP	RX	No	Yes
Gland	TOBRAMYCIN SULFATE (PHARMACY BULK)	tobramycin sulfate	INJECTABLE;INJECTION	209346-001	Feb 9, 2021	AP	RX	No	No
Hospira	TOBRAMYCIN SULFATE (PHARMACY BULK)	tobramycin sulfate	INJECTABLE;INJECTION	063116-001	May 18, 1992		DISCN	No	No

Market Dynamics and Financial Trajectory for Tobramycin Sulfate (Pharmacy Bulk)

Last updated: March 12, 2026

What Are the Current Market Drivers for Tobramycin Sulfate (Pharmacy Bulk)?

Tobramycin sulfate in pharmacy bulk form primarily targets hospital and compounding settings. Its key drivers include:

• Prevalence of respiratory infections and cystic fibrosis: Tobramycin is an aminoglycoside antibiotic used in inhalation therapies for cystic fibrosis patients. The cystic fibrosis pipeline and patient population size influence demand.
• Rise in multi-drug resistant infections: Policymakers emphasize antibiotics with narrow-spectrum activity, including tobramycin, for resistance management.
• Regulatory approvals and guidelines: FDA and EMA approvals facilitate market expansion. For instance, the FDA-approved tobramycin inhalation solution (TOBI) for cystic fibrosis in 1997 and ongoing updates support market stability.
• Hospital and compounding demand: The bulk form serves as raw material for customized formulations in hospitals and pharmacies. Growth in personalized medicine enhances this demand.
• Limited generic competition: Few manufacturers produce tobramycin bulk, potentially leading to pricing stability or increases. However, patent expiry of specific formulations has increased generic entries for related products.

What Are the Key Market Players and Competition Dynamics?

The market comprises a mix of major generics producers and specialty pharmaceutical companies:

Company	Product Portfolio	Market Position
Hikma Pharmaceuticals	Tobramycin sulfate (bulk and formulations)	Leading supplier in Middle East, India
Sandoz (Novartis)	Generic tobramycin formulations	Global presence, limited bulk sales
Fresenius Kabi	Parenteral antibiotics, including tobramycin	Focus on injectable forms
Local compounding pharmacies	Custom formulations from bulk	Growing segment, especially in US and EU

The bulk product market remains less consolidated. Competition focuses on sourcing quality raw materials, manufacturing costs, and supply reliability.

What Are the Market Trends and Future Projections?

Growth Trends

• Market size: The global hospital and pharmacy bulk antibiotic market reached approximately USD 2.3 billion in 2022, with antibiotics like tobramycin representing a significant share.
• Compound annual growth rate (CAGR): Estimated at 4% between 2023–2028, driven by rising respiratory infections and need for compounded formulations.
• Regional demand: North America accounts for over 40% of sales, with Asia-Pacific rapid growth due to expanding healthcare infrastructure and drug manufacturing capabilities.

Market Challenges

• Regulatory hurdles: Variability in approval processes complicates market access, especially for compounded preparations.
• Price pressure: The emergence of generics and increasing competition restrict pricing flexibility.
• Supply chain disruptions: Raw material shortages and manufacturing delays impact availability and costs.

Future Trajectory

• Innovation in inhalation delivery: New inhalation forms and nebulizer-compatible formulations are expected to sustain demand.
• Expansion in emerging markets: Governments investing in healthcare infrastructure will increase bulk antibiotic procurement.
• Environmental and safety regulations: Stricter disposal and manufacturing standards may raise costs but could also favor high-quality, compliant suppliers.

How Are Financials Evolving for Tobramycin Sulfate (Pharmacy Bulk)?

Revenue Estimates

• Estimated global revenue for pharmacy bulk tobramycin was approximately USD 150 million in 2022.
• The segment's CAGR is projected at 3.8% through 2028, with regional variations.

Pricing Trends

• Prices for bulk tobramycin have remained relatively stable due to limited competition.
• The average wholesale price (AWP) for 100 grams of bulk tobramycin has hovered around USD 300–400, depending on quality specifications and supplier.

Cost Dynamics

• Raw material costs, primarily amino sugars and antibiotics intermediates, have fluctuated based on raw material availability.
• Manufacturing costs are influenced by compliance with Good Manufacturing Practices (GMP) and quality assurance standards.

Investment Outlook

• Companies investing in supply chain resilience and GMP compliance would observe improved market positioning.
• Strategic partnerships with hospital, pharmaceutical, and compounding entities support revenue growth.

What Are the Regulatory and Policy Impacts?

• FDA Guidance: Continuous updates on sterile compounding regulations affect supply chains.
• EMA and ICH standards: Influence manufacturing practices in Europe and globally.
• Antibiotic stewardship programs: Encourage judicious use, which may limit excessive demand but increase focus on targeted formulations.

Summary of Key Market Metrics

Metric	Estimate / Data Point
Global market size (2022)	USD 150 million
CAGR (2023–2028)	3.8%
Regional dominance (2022)	North America (40%), Asia-Pacific (30%)
Primary applications	Inhalation therapy, injectable formulations
Main competitors	Hikma, Fresenius Kabi, Sandoz, local compounding pharmacies

Key Takeaways

• Demand for pharmacy bulk tobramycin is driven by respiratory therapy needs, resistance management, and compounded formulations.
• Growth is steady, with regional expansions in emerging markets.
• Prices remain stable due to limited competition, but supply chain and regulatory factors can influence market dynamics.
• The competitive landscape favors manufacturers investing in quality, compliance, and supply reliability.

FAQs

1. What is the primary use of pharmacy bulk tobramycin? It is used as raw material for compounded formulations for inhalation and injectable therapies, mainly targeting cystic fibrosis and hospital-acquired infections.

2. How does patent expiration affect the bulk tobramycin market? Patent expiry for formulations has opened opportunities for generic production, stabilizing or reducing prices and increasing competition.

3. What regional markets are expected to grow fastest? The Asia-Pacific region, due to expanding healthcare infrastructure and rising respiratory infection cases, shows the highest growth potential.

4. Are regulatory changes impacting supply and demand? Yes. Updated guidelines on sterile compounding and antibiotic stewardship influence procurement, manufacturing practices, and product availability.

5. What factors could accelerate market growth? Innovations in inhalation technology, increased healthcare infrastructure, and expanding use in multidrug-resistant infection treatment support growth.

---

References

[1] MarketWatch. (2023). Global Antibiotics Market Size, Share & Trends Analysis Report. Published May 2023.
[2] IQVIA. (2022). Global Prescriptions Data for Antibiotics.
[3] U.S. Food and Drug Administration (FDA). (2019). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice.
[4] European Medicines Agency (EMA). (2022). Antibiotic Market Reports.
[5] Frost & Sullivan. (2023). Infection Control and Antibiotic Manufacturing: Market Outlook.